Literature DB >> 12117937

One of two copies of the gene for the activatable shiga toxin type 2d in Escherichia coli O91:H21 strain B2F1 is associated with an inducible bacteriophage.

Louise D Teel1, Angela R Melton-Celsa, Clare K Schmitt, Alison D O'Brien.   

Abstract

Shiga toxin (Stx) types 1 and 2 are encoded within intact or defective temperate bacteriophages in Stx-producing Escherichia coli (STEC), and expression of these toxins is linked to bacteriophage induction. Among Stx2 variants, only stx(2e) from one human STEC isolate has been reported to be carried within a toxin-converting phage. In this study, we examined the O91:H21 STEC isolate B2F1, which carries two functional alleles for the potent activatable Stx2 variant toxin, Stx2d, for the presence of Stx2d-converting bacteriophages. We first constructed mutants of B2F1 that produced one or the other Stx2d toxin and found that the mutant that produced only Stx2d1 made less toxin than the Stx2d2-producing mutant. Consistent with that result, the Stx2d1-producing mutant was attenuated in a streptomycin-treated mouse model of STEC infection. When the mutants were treated with mitomycin C to promote bacteriophage induction, Vero cell cytotoxicity was elevated only in extracts of the Stx2d1-producing mutant. Additionally, when mice were treated with ciprofloxacin, an antibiotic that induces the O157:H7 Stx2-converting phage, the animals were more susceptible to the Stx2d1-producing mutant. Moreover, an stx(2d1)-containing lysogen was isolated from plaques on strain DH5alpha that had been exposed to lysates of the mutant that produced Stx2d1 only, and supernatants from that lysogen transformed with a plasmid encoding RecA were cytotoxic when the lysogen was induced with mitomycin C. Finally, electron-microscopic examination of extracts from the Stx2d1-producing mutant showed hexagonal particles that resemble the prototypic Stx2-converting phage 933W. Together these observations provide strong evidence that expression of Stx2d1 is bacteriophage associated. We conclude that despite the sequence similarity of the stx(2d1)- and stx(2d2)-flanking regions in B2F1, Stx2d1 expression is repressed within the context of its toxin-converting phage while Stx2d2 expression is independent of phage induction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117937      PMCID: PMC128153          DOI: 10.1128/IAI.70.8.4282-4291.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157:H7: Shiga toxin as a phage late-gene product.

Authors:  G Plunkett; D J Rose; T J Durfee; F R Blattner
Journal:  J Bacteriol       Date:  1999-03       Impact factor: 3.490

2.  Evolutionary relationships among diverse bacteriophages and prophages: all the world's a phage.

Authors:  R W Hendrix; M C Smith; R N Burns; M E Ford; G F Hatfull
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

3.  Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release.

Authors:  M N Neely; D I Friedman
Journal:  Mol Microbiol       Date:  1998-06       Impact factor: 3.501

4.  An ileX tRNA gene is located close to the Shiga toxin II operon in enterohemorrhagic Escherichia coli O157 and non-O157 strains.

Authors:  H Schmidt; J Scheef; C Janetzki-Mittmann; M Datz; H Karch
Journal:  FEMS Microbiol Lett       Date:  1997-04-01       Impact factor: 2.742

Review 5.  Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world.

Authors:  G L Armstrong; J Hollingsworth; J G Morris
Journal:  Epidemiol Rev       Date:  1996       Impact factor: 6.222

6.  Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin.

Authors:  A Matsushiro; K Sato; H Miyamoto; T Yamamura; T Honda
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

7.  Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens.

Authors:  S Fuchs; I Mühldorfer; A Donohue-Rolfe; M Kerényi; L Emödy; R Alexiev; P Nenkov; J Hacker
Journal:  Microb Pathog       Date:  1999-07       Impact factor: 3.738

8.  Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome.

Authors:  H Ito; A Terai; H Kurazono; Y Takeda; M Nishibuchi
Journal:  Microb Pathog       Date:  1990-01       Impact factor: 3.738

9.  Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells.

Authors:  M L McKee; A R Melton-Celsa; R A Moxley; D H Francis; A D O'Brien
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates.

Authors:  D Piérard; G Muyldermans; L Moriau; D Stevens; S Lauwers
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

View more
  39 in total

1.  A newly discovered verotoxin variant, VT2g, produced by bovine verocytotoxigenic Escherichia coli.

Authors:  P H M Leung; J S M Peiris; W W S Ng; R M Robins-Browne; K A Bettelheim; W C Yam
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

2.  Shiga toxin 2-converting bacteriophages associated with clonal variability in Escherichia coli O157:H7 strains of human origin isolated from a single outbreak.

Authors:  Maite Muniesa; Mercè de Simon; Guillem Prats; Dolors Ferrer; Helena Pañella; Juan Jofre
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

3.  Presence of activatable Shiga toxin genotype (stx(2d)) in Shiga toxigenic Escherichia coli from livestock sources.

Authors:  Kari S Gobius; Glen M Higgs; Patricia M Desmarchelier
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

4.  SOS regulation of the type III secretion system of enteropathogenic Escherichia coli.

Authors:  Jay L Mellies; Kenneth R Haack; Derek C Galligan
Journal:  J Bacteriol       Date:  2007-01-19       Impact factor: 3.490

5.  Shiga-toxigenic Escherichia coli-inoculated neonatal piglets develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome.

Authors:  J F Pohlenz; K R Winter; E A Dean-Nystrom
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 6.  Enteropathogenic and enterohemorrhagic Escherichia coli virulence gene regulation.

Authors:  Jay L Mellies; Alex M S Barron; Anna M Carmona
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

7.  Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors.

Authors:  Malene Gantzhorn Pedersen; Claus Hansen; Erik Riise; Søren Persson; Katharina E P Olsen
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

8.  Quantification of Shiga toxin-converting bacteriophages in wastewater and in fecal samples by real-time quantitative PCR.

Authors:  Lejla Imamovic; Elisenda Ballesté; Juan Jofre; Maite Muniesa
Journal:  Appl Environ Microbiol       Date:  2010-07-09       Impact factor: 4.792

9.  Top-down proteomic identification of Shiga toxin 2 subtypes from Shiga toxin-producing Escherichia coli by matrix-assisted laser desorption ionization-tandem time of flight mass spectrometry.

Authors:  Clifton K Fagerquist; William J Zaragoza; Omar Sultan; Nathan Woo; Beatriz Quiñones; Michael B Cooley; Robert E Mandrell
Journal:  Appl Environ Microbiol       Date:  2014-02-28       Impact factor: 4.792

10.  Shiga toxin-producing Escherichia coli-associated kidney failure in a 40-year-old patient and late diagnosis by novel bacteriologic and toxin detection methods.

Authors:  Louise D Teel; Brett R Steinberg; Naomi E Aronson; Alison D O'Brien
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.